Merck & Co. Indefinite- lived intangible impairment increased by 31.4% to $55.41B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 31.4%, from $42.16B to $55.41B. Over 5 years (FY 2020 to FY 2025), Indefinite- lived intangible impairment shows an upward trend with a 10.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in impairment charges signals a decline in the value of the company's intangible assets, potentially indicating poor acquisition outcomes or changing market conditions.
This represents the gross value of indefinite-lived intangible assets, excluding goodwill, that have been subject to imp...
Varies significantly based on M&A history; companies with frequent acquisitions often show higher volatility in this metric.
other_intangible_assets_gross_excluding_goodwill| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $42.44B | $41.75B | $41.60B | $42.16B | $55.41B |
| QoQ Change | — | -1.6% | -0.3% | +1.3% | +31.4% |
| YoY Change | — | -1.6% | -0.3% | +1.3% | +31.4% |